Search
Now showing items 1-2 of 2
Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: Effects of dosage and route on safety and immunogenicity
(2007)
Background: Two parallel studies evaluated safety and immunogenicity of a prophylactic HIV-1 vaccine in 192 HIV-seronegative, low-risk
volunteers. Modified vaccinia virus Ankara (MVA) and plasmid DNA (pTHr) expressed HIV-1 ...
Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa
(2008)
Summary: The safety and immunogenicity of plasmid pTHr DNA, modified vaccinia virus Ankara
(MVA) human immunodeficiency virus type 1 (HIV-1) vaccine candidates were evaluated in four
Phase I clinical trials in Kenya and ...